Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), a United States-based biotechnology company, announced on Wednesday that Novartis has completed patient enrolment for the pivotal Phase three Lp(a) HORIZON cardiovascular outcomes study of pelacarsen.

The company has enrolled 8,325 participants in the study.

The study is assessing the safety and efficacy of pelacarsen in decreasing cardiovascular events in patients with cardiovascular disease and increased level of Lp(a). Topline data from the study are likely to be revealed in 2025.

Pelacarsen is an investigational antisense medicine aimed at inhibiting the production of apolipoprotein(a) in the liver to decrease elevated lipoprotein(a) or Lp(a) levels, an independent, inherited and causal risk factor for cardiovascular disease (CVD) and calcific aortic valve stenosis.

Novartis licensed pelacarsen from Ionis in 2019.